Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.6.0.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 11, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Mar. 22, 2010
Debt instruments principal amount   $ 1,466    
Debt maturity date Jun. 15, 2017        
Common stock par value   $ 0.0005 $ 0.0005    
Adjustments to reduce inventory for excess or obsolete inventory   $ 1,600 $ 501    
Cash balance   441      
Bank balance   551      
Amount of bank balance covered by federal depository insurance   309      
Amount of bank balance uninsured   242      
Allowance for bad debt      
Provision for sales allowances   108 83    
Prepaid expenses and other current assets   263 854    
Share-based compensation expense   $ 1 135 $ 1,000  
Equity ownership interest   50.00%     50.00%
Advertising and incentive promotion expenses   $ 9,700 8,500 10,900  
Research and development   575 1,078 $ 1,322  
Estimated Future Sales Return [Member]          
Accrued liabilities   1,200 1,400    
Cooperative Incentive [Member]          
Accrued liabilities   1,500 $ 786    
TK Supplements [Member]          
Adjustments to reduce inventory for excess or obsolete inventory   383      
Potential Division Sale [Member]          
Adjustments to reduce inventory for excess or obsolete inventory   $ 606      
OTC Health Care [Member]          
Revenue, percentage   84.00% 90.00% 94.00%  
Secured Promissory Notes [Member]          
Debt instruments principal amount   $ 1,500      
Debt maturity date   Jun. 15, 2017      
2015 Equity Line of Credit [Member]          
Working capital   $ 2,800      
Number of common stock issued during period   2,450,000      
Common stock par value   $ 0.0005